Application of trilobatin to cerebral ischemia-reperfusion injury preventing and treating drug

A technology of cerebral ischemia-reperfusion and trelobatin, which is applied in the field of pharmacy, can solve the problem of no anti-cerebral ischemia-reperfusion injury, achieve the effect of preventing and treating cerebral ischemia-reperfusion injury, good therapeutic effect, and easy access

Inactive Publication Date: 2018-07-20
ZUNYI MEDICAL UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no report on anti-cerebral ischemia-reperfusion injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trilobatin to cerebral ischemia-reperfusion injury preventing and treating drug
  • Application of trilobatin to cerebral ischemia-reperfusion injury preventing and treating drug
  • Application of trilobatin to cerebral ischemia-reperfusion injury preventing and treating drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030]A kind of application of trilobatin in preventing and treating cerebral ischemia-reperfusion injury medicine, take trilobatin 5g, medicinal starch 75g, microcrystalline cellulose 20g, medicinal starch is first dried, pass through 120 mesh sieves, and then Mix with trilobatin and microcrystalline cellulose, pass through a 120-mesh sieve twice, fill in hard capsules, and make 1000 capsules of the present invention; each hard capsule contains 0.5 mg of the main ingredient.

Embodiment 2

[0032] A kind of application of trilobatin in preventing and treating cerebral ischemia-reperfusion injury medicine, take trilobatin 5g, hypromellose 6g, carboxymethyl starch sodium 10g, microcrystalline cellulose 8g, lactose 115g, starch 50g, hard Magnesium stearate 1g; fully mix trelobatin with hypromellose, sodium starch glycolate, microcrystalline cellulose, lactose, starch, magnesium stearate and put it into a high-speed blender, spray with appropriate amount of water, Control it at 3-4%, then compress into tablets, make 1000 tablets, and coat with film.

Embodiment 3

[0034] A kind of application of trilobatin in the prevention and treatment of cerebral ischemia-reperfusion injury medicine, take trilobatin 5g, add 400 ml polyethylene glycol 200 to dissolve, then add appropriate amount of distilled water to dilute, then add appropriate amount of sucrose and adjust the volume to 1000 ml, stir well, filter, fill into 10 ml or 20 ml each, sterilized package.

[0035] The invention adopts a rat model of focal cerebral ischemia-reperfusion injury to study the preventive effect of trilobatin on cerebral ischemia-reperfusion injury. Different concentrations of trilobatin (5, 10, 20 mg / kg) were given prophylactically for 7 days, and the MCAO model was prepared by suture method. After 2 hours of ischemia, reperfusion was performed for 24 hours. The results showed that trilobatin had a concentration-dependent preventive effect on cerebral ischemia-reperfusion injury, and significantly reduced the release of pro-inflammatory factors (TNF-α, IL-1β and I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of trilobatin to a cerebral ischemia-reperfusion injury preventing and treating drug. 5 g of trilobatin, 75 g of medicinal starch and 20 g of microcrystalline cellulose are taken, the medicinal starch is dried firstly, sieved by a 120-mesh sieve and then mixed with trilobatin and microcrystalline cellulose, the mixture is sieved by the 120-mesh sieve twice, hard capsules are filled with the mixture, 1000 capsules are prepared, and each hard capsule contains 0.5 mg of the main drug ingredients. Trilobatin is used for preparing the cerebral ischemia-reperfusion injury preventing and treating drug, and animal experiments prove that prepared pharmaceutical composition can prevent and treat cerebral ischemia-reperfusion injury. Materials are widely sourcedand easily available, and trilobatin is simple, easy and good in treatment effect when used for preparing the drug.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to the application of trilobatin in the prevention and treatment of cerebral ischemia-reperfusion injury. Background technique [0002] Stroke, also known as cerebral apoplexy or cerebrovascular accident, is a group of diseases whose main clinical manifestations are cerebral ischemia or hemorrhagic injury. About 80% of them are ischemic strokes caused by focal cerebral ischemia caused by arterial occlusion, and 20% are hemorrhagic strokes. Stroke has the characteristics of high morbidity, high disability rate, high fatality rate, and unpredictable characteristics. It has become a major disease that threatens human health and affects the quality of life, causing heavy mental and economic burdens to society and families. In 2016, The Lancet published a new analysis of global causes of death by the International Burden of Disease Group, in which the number of deaths from cerebrovascular diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61P9/10
CPCA61K31/7034
Inventor 龚其海高健美韦余晏灵莉
Owner ZUNYI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap